Increased APP processing and the Aβ peptides can inhibit the PI3K-Akt-mTOR pathway, and reduced mTOR activity has been reported in both APPsw/Tg 2576 mice and human AD patients [96-116]. This evidence concerns the gene AKT1 and Alzheimer disease.